-?7S=@TJU/1-%TC1=34%3%$4%V;7&54%L;&34ZH?>°°3%$4^)±34MC54²C34ì<L
!$NHH!
;WD=?-27-+?-,B=0/0?-1+=/1,=1/1Y/?/02+-C0/1Y61?=B;D-+?=B/-+=-=
/1FB-i/7)T*fJ-1TS/+B;D/;7%3%$%%H)"'5524%(f)$)*
LC@=7,-1h%MC1\=7OXfF-+?=B/-7,=1/1Y/?/0"=A/@=,/;7;Y8%A-?U;Y=1=0/0-1@,-1-Y=,=1?CA@-?=)T*f!BCY0%3%%5%)5"3H((23H5)f)$(*
K-8-\-e-d%g-??CE%S-B+U-/,!%=?-7f6A/@=,/;7;Y8-1@B/0\W-+?;B0W;B/0;7-?/;1;W60+U=B/+U/-+;/7AB;@C+/1YJMR2S2?8A==>?=1@=@20A=+?BC, 27-+?-,-0=/1-7-BY=ZfEfS=@/+-7J=1?=B)T*fO1?/,/+B;DOY=1?0JU=,;?U=B%3%$'%H("4%$%24%$Nf)$N*
F=12O,/X%X;@BjYC=i2F-k;T%OB07-1K%=?-7fO,C7?/1-?/;1-70CB9=8;WB/0\W-+?;B0W;B/1W=+?/;1e/?U=>?=1@=@20A=+?BC,D=?-27-+?-,-0=2AB;@C+/1Y=1?=B;D-+?=B/-+=-=/11;1U;0A/?-7/i=@A-?/=1?0)T*fJ7/1#1W=+?!/0%3%%5%45")N32)5%f)$5*d-1YJ#%JU=;1YKE%JUC1Y!X%=?-7fJ7/1/+-7W=-?CB=0-1@;C?+;,=;W+;,,C1/?82;10=?D7;;@0?B=-,/1W=+?/;10+-C0=@D8=>?=1@=@20A=+?BC,D=?-27-+?-,-0=2AB;@C+/1Y60+U=B/+U/-+;7/)T*f6CBTJ7/1S/+B;D/;7#1W=+?!/0%3%%N%3("NH2NNf)3%*
X;@BjYC=i2F-k;T%P/+l16%g/.l1P%=?-7fJ;,,C1/?82;10=?D-+?=B=,/-@C=?;=>?=1@=@20A=+?BC,D=?-27-+?-,-0=2AB;@C+/1Y60+U=B/+U/-+;7/"B/0\W-+?;B0-1@AB;Y1;0/0)T*fJ7/1#1W=+?!/0%3%$%%H%"4%24Nf)3$*
G==TO%d-1YJ#%T;;6T%=?-7f6A/@=,/;7;Y8-1@+7/1/+-7W=-?CB=0;W+;,,C1/?82;10=?D-+?=B=,/-+-C0=@D8=>?=1@=@20A=+?BC, 27-+?-,-0=2AB;@C+/1Yd7=D0/=77-A1=C,;1/-=)T*fS/+B;D!BCYX=0/0?%3%$$%$("3)(23('f)33*
G/1YMd%R/;1YT%hCh%=?-7fSC7?/+=1?=B-1?/,/+B;D/-70C0+=A?/D/7/?80CB9=8;WYB-,21=Y-?/9=D-+?=B/-/0;7-?=@WB;,A-?/=1?0e/?U+;,,C1/?82-+mC/B=@/1W=+?/;10/1?U=P=;A7=n0X=ACD7/+;WJU/1-)T*fO1?/,/+B;DOY=1?0JU=,;?U=B%3%%)%H%"'(42'(Nf)3'*K-e0=BEP%F;C+U/77;1Ed%K;D-1!T%=?-7f6,=BY=1+=;WU/YU7=9=70;W=>?=1@=@20A=+?BC,2D=?-27-+?-,-0=2AB;@C+/1YYB-,21=Y-?/9=D-+/77//1?U=O0/-2P-+/W/+B=Y/;1"@-?-WB;,?U=E?C@8W;BS;1/?;B/1YO1?/,/+B;D/-7X=0/0?-1+=MB=1@0#ESOXM$AB;YB-,%3%%()T*fO1?/,/+B;DOY=1?0JU=,;?U=B%3%%5%H'"'3N%2'3N4f)34*
WT% ØÔ%_x×%Df3%%5/3%$%^Z[ÚÃÄòw«
©rs/EF§\]^t¼ÃÄ/cd)T*fZHýö¶EF
°°%3%$3%'H"$$'2
$$5f)3H*ê² %õîú%UÞ$%Df«©rs/ \]=º78¼
ÇebÈ 2ÉÊËÌÁydàÃÄcd)T
*fZH?@\]>°°%3%%N%$N"$)3(2
$)3N%$3'$f)3)*
ûÀô%üýX% 9 %DfZ[,nH©=º78¼¶9
:;<=¼ebÈ ÉÊËÌ&ùª3P)T
*fZHyz?>°°%3%%4%3("H5%2
H5'f)3(*
hCh%T/E%JU=1h%=?-7fX=0/0?-1+=;W0?B-/10AB;@C+/1Y=>?=1@=@20A=+?BC,D=?-27-+?-,-0=0-1@Y=1;?8A=@/0?B/DC?/;1/1JU/1-)T*fT#1W=+?%3%%(%H4"H'2H(f
)3N*de%ß þ%R,ï%Dfb:H©J
MR2SªebÈ ÉÊËÌ=º78¼¶9:;<=¼Á3P)T*fZHyz?>°
°%3%%5%'3"$$$42
$$$5f)35*
oUC;J%G/Rp%o;1Yoh%=?-7f6A/@=,/+P7-0,/@+-BB8/1YD7-#JMR2S2$H$/1d7=D0/=77-A=1C,;1/-=/1JU/1-)T*fPG;E"1=%3%$'%N"=H3333f)'%*
J7/1/+-7-1@G-D;B-?;B8E?-1@-B@0#10?/?C?=fS$%%2E$5P=BW;B,-1+=0?-1@-B@0W;B-1?/,/+B;D/-70C0+=A?/D/7/?8?=0?/1Y"?e=1?/=?U/1W;B,-?/;1-70CAA7=,=1?)E*fq-81=%ZEO"J7/1/+-7-1@G-D;B-?;B8E?-1@-B@0#10?/?C?=%3%%5f)'$*
G=+7=B+mX%J-1?l1X%g/0\=Jg%=?-7f6>A=B?BC7=0/1-1?/,/+B;D/-70C0+=A?/D/7/?8?=0?/1Y)E*"G*f)3%$'2$323%*fU??A"**eeef=C+-0?f;BY*W/7=-@,/1*0B+*,=@/-*P!b0*46EJS#!rG/DB-B8*'PCD7/+-?/;10*6ZJOEMr!;+C,=1?0*"?U=Br!;+C,=1?0*6ZJOEMr6>A=B?rBC7=0rW/1-7rOAB/7r3%%N%4%(fP@Wf)'3*
J7/1/+-7-1@G-D;B-?;B8E?-1@-B@0#10?/?C?=fS$%%2E3%P=BW;B,-1+=0?-1@-B@0W;B-1?/,/+B;D/-70C0+=A?/D/7/?8?=0?/1Y"?e=1?/=?U/1W;B,-?/;1-70CAA7=,=1?)E*fq-81=%ZEO"J7/1/+-7
-1@G-D;B-?;B8E?-1@-B@0#10?/?C?=%3%$%f
)''*
G=+7=B+mX%J-1?l1X%FB;e1!b%=?-7f6ZJOEM=>A=B?BC7=0/1-1?/,/+B;D/-70C0+=A?/D/7/?8?=0?/1Y)T*fJ7/1S/+B;D/;7#1W=+?%3%$'%$5"$4$2$)%f)'4*
O1@=0!%JB-/YqOfMB=-?,=1?;W/1W=+?/;10e/?U6EFG2AB;@C+/1Y;BY-1/0,0"AU-B,-+;\/1=?/+-1@AU-B,-+;@81-,/++;10/@=B-?/;10)T*fJ7/1S/+B;D/;7#1W=+?%3%%H%$$ECAA7)"$%2$(f)'H*
S-Y7/;!%"1YJ%F-1=9/+/C0SO%=?-7f!=?=B,/1-?/;1;W?U=/19/9;AU-B,-+;@81-,/+AB;W/7=;W+=W=A/,=-Y-/10?=>?=1@=@20A=+?BC,2D=?-27-+?-,-0=2AB;@C+/1Y60+U=B/+U/-+;7/-?9-B/;C0/1;+C7-)T*fO1?/,/+B;DOY=1?0JU=,;?U=B%3%%4%4N"$54$2$54(f)')*
P-?=B0;1!G%d;qJ%V;1g;??D=BYO%=?-7f"C?+;,=;W+=AU-7;0A;B/1?B=-?,=1?W;B0=B/;C0/1W=+?/;10@C=?;-AA-B=1?780C0+=A?/D7=;BY-1/0,0AB;@C+/1Y=>?=1@=@20A=+?BC,D=?-27-+?-,-0=0"/,A7/+-?/;10W;B?U=+7/1/+-7,/+B;D/;7;Y87-D;B-?;B8)T*fTJ7/1S/+B;D/;7%3%%$%'5"33%)233$3f)'(*
K;PG%JU-1qS%M0-1Ydq%=?-7fF-+?=B=,/-+-C0=@D860+U=B/+U/-+;7/AB;@C+/1Y=>?=1@=@20A=+?BC,D=?-27-+?-,-0="-+-0=2+;1?B;70?C@8;WB/0\W-+?;B0-1@;C?+;,=0)T*fE+-1@T#1W=+?!/0%3%%3%'4"H)(2H('f)'N*
P-B\hE%O@-,02K-@C+UTS%EUC??dO%=?-7fJ7/1/+-7-1@,/+B;D/;7;Y/++U-B-+?=B/0?/+0;W+=AU-7;0A;B/12B=0/0?-1?60+U=B/+U/-+;7/-??UB==+=1?=B0/1?U=Z1/?=@E?-?=0)T*fO1?/,/+B;DOY=1?0JU=,;?U=B%3%$3%H)"$N(%2$N()f)'5*
d-1YJ#%q/hS%G==Sh%=?-7f6A/@=,/;7;Y8-1@B/0\W-+?;B0;W+;,,C1/?8;10=?/1W=+?/;10+-C0=@D8=>?=1@=@20A=+?BC, 27-+?-,-0=2AB;@C+/1Y60+U=B/+U/-+;7/0?B-/10)T*fTJ7/1S/+B;D/;7%3%$3%H%"'$32'$(f)4%*
F=B?b%G-BB;mC=F%P-CY-,2FCB?iJ%=?-7fPB=?B-10A7-1?W=+-7+-BB/-Y=;W=>?=1@=@20A=+?BC, 27-+?-,-0=2AB;@C+/1Y61?=B;D-+?=B/-+=-=-1@/1W=+?/;1-W?=B7/9=B?B-10A7-1?%bB-1+=)T*f6,=BY#1W=+?!/0%3%$3%$N"5%N25$)f)4$*
!=77/1Y=BXP%G=98SS%XU;@=0O%=?-7fECB9/9/1YE=A0/0J-,A-/Y1"/1?=B1-?/;1-7YC/@=7/1=0W;B,-1-Y=,=1?;W0=9=B=0=A0/0-1@0=A?/+0U;+\%3%$3)T*f#1?=10/9=J-B=S=@%3%$'%'5"$)H233Nf)43*
P-?=B0;1!G%d;qJ%V;1g;??D=BYO%=?-7fO1?/D/;?/+?U=B-A8W;Bd7=D0/=77-A1=C,;1/-=D-+?=B=,/-"/,A7/+-?/;10;WAB;@C+?/;1;W=>?=1@=@20A=+?BC,D=?-27-+?-,-0=0)T*fJ7/1#1W=+?!/0%3%%4%'5"'$2'(f)4'*
MC,D-B=77;S%EA-1CM%E-1YC/1=??/S%=?-7fF7;;@0?B=-,/1W=+?/;10+-C0=@D8=>?=1@=@20A=+?BC,2D=?-27-+?-,-0=2AB;@C+/1Yd7=D0/=77-A1=C,;1/-="B/0\W-+?;B0%,;7=+C7-B=A/@=,/;7;Y8%-1@+7/1/+-7;C?+;,=)T*fO1?/,/+B;DOY=1?0JU=,;?U=B%3%%)%H%"45N2H%4f)44*
V-B@-\-0do%M-10-B7/gE%X-W-/7/@/0P#%=?-7fJ-BD-A=1=,09=B0C0-7?=B1-?/9=-1?/D/;?/+0W;B?U=?B=-?,=1?;WD-+?=B-=,/-@C=?;61?=B;D-+?=B/-+=-=AB;@C+/1Y=>?=1@=@20A=+?BC, 27-+?-,-0=0"-080?=,-?/+B=9/=e-1@,=?-2-1-780/0)T*fTO1?/,/+B;DJU=,;?U=B%3%$3%)("3(5'23N%'f)4H*
MC1\=7OX%K-B?,-1FT%d-A7-1EG%=?-7fPB-+?/+=YC/@=7/1=0W;B?U=,-1-Y=,=1?;WD-+?=B/-7,=1/1Y/?/0)T*fJ7/1#1W=+?!/0%3%%4%'5"$3)(2$3N4f)4)*
q-@/TO%E=7-e/bf6>?=1@=@20A=+?BC,D=?-27-+?-,-0=d7=D0/=77-A1=C,;1/-=,=1/1Y/?/0?B=-?=@e/?U?/Y=+8+7/1=)T*fO11E-C@/S=@%3%%5%35"3'5234%f
)4(*
-f¥%²ÿþ% %Df ÕOÙgÞ , ´/Ç6EFG0xPy/¼Á N¼A/)T*fH Ä>°°%3%$3%3("H3$2H33f
)4N*
ZH?>ã ^>nã%Z[? µã 2? nãf
Z[Z/ϽÓ67_QÉi6N¼Ä¥¢£Ç5)o)T
*fZH >°°%3%$3%''")5'2
)5)f)45*
!/=?B/+U6E%F/=0=BZ%bB-1\Z%=?-7fJ=W?B/->;1=9=B0C0;?U=B
【医脉通指南频道】2014+中国产超广谱β-内酰胺酶肠杆菌科细菌感染应对策略专家共识_临床医学_医药卫生_专业资料 暂无评价0人阅读0次下载举报文档...
产超广谱β-内酰胺酶细菌感染防治专家共识_医药...β2lactamases, ESBL s) 是肠杆菌科细菌 内对β... 2014中国产超广谱β-内酰... 10页 1下载券 产...
产超广谱β-内酰胺酶肠杆菌科细菌的耐药性分析_专业资料。目的监测产超广谱β-内酰胺酶肠杆菌科细菌的耐药情况,提高治疗效果,控制感染传播。方法采用K-B药敏...
某院产超广谱β-内酰胺酶肠杆菌科细菌检出率及耐药性分析_中医中药_医药卫生_专业资料。检验 医学 与临床201 3年 6月第1 0卷第l 2期 Lab Med Ciin,June...
产超广谱β-内酰胺酶细菌感染防治专家共识_医药...在肠杆菌科细菌中以肺炎克雷伯菌最为常见,产 ...
肠杆菌科细菌产超广谱β-内酰胺酶的流行病学特征研究_专业资料。目的了解西安市肠杆菌科细菌中产超广谱哥内酰胺酶(ESBLs)的流行特征及危险因素。方法收集1年间西安...
产超广谱β内酰胺酶对肠杆菌科细菌血流感染病死率的影响:荟萃分析_临床医学_医药卫生_专业资料。中国感染与化疗杂志 201 3年 3月2 0日第1 3卷第 2期Chin ...
产超广谱β-内酰胺酶细菌感染防治专家共识_医药...β-lactamase,ESBLs)是肠杆菌 科细菌对β-内酰胺类...
【医脉通指南频道】2014+中国产超广谱β-内酰胺酶肠杆菌科细菌感染应对策略专家共识_临床医学_医药卫生_专业资料 暂无评价0人阅读0次下载举报文档...
热门文档